Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $400.00 price objective on the biopharmaceutical company's stock. HC Wainwright's price target indicates a potential upside of 48.18% from the stock's previous close.

A number of other brokerages also recently weighed in on ALNY. Chardan Capital reaffirmed a "buy" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. Citigroup boosted their price objective on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an "equal weight" rating in a research note on Friday, July 12th. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Six analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $294.50.

Alnylam Pharmaceuticals Trading Down 1.4 %

Alnylam Pharmaceuticals stock traded down $3.96 during midday trading on Monday, hitting $269.95. The stock had a trading volume of 781,879 shares, compared to its average volume of 870,820. The business has a fifty day moving average price of $274.61 and a 200 day moving average price of $227.00. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market cap of $34.66 billion, a P/E ratio of -103.05 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The company's quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.15 earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals will post -2.74 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 20,250 shares of the firm's stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares of the company's stock, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now directly owns 136 shares of the company's stock, valued at $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of Alnylam Pharmaceuticals by 32.3% in the 1st quarter. Commonwealth Equity Services LLC now owns 5,594 shares of the biopharmaceutical company's stock valued at $836,000 after purchasing an additional 1,365 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Alnylam Pharmaceuticals by 63.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 62,415 shares of the biopharmaceutical company's stock worth $9,328,000 after purchasing an additional 24,228 shares in the last quarter. Janney Montgomery Scott LLC increased its position in Alnylam Pharmaceuticals by 47.4% during the first quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company's stock worth $415,000 after buying an additional 892 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Alnylam Pharmaceuticals by 7.7% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,849 shares of the biopharmaceutical company's stock worth $575,000 after buying an additional 274 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.